Essential pre-treatment imaging examinations in patients with endoscopically-diagnosed early gastric cancer

被引:2
|
作者
Horisoko, Eri [1 ]
Tsushima, Yoshito [1 ]
Taketomi-Takahashi, Ayako [1 ]
Tokunaga, Mari [2 ]
Endo, Keigo [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Diagnost Radiol & Nucl Med, Gunma, Japan
[2] Isesaki City Hosp, Dept Radiol, Gunma, Japan
关键词
KRUKENBERG TUMOR; CARCINOMA; METASTASIS; RECURRENCE;
D O I
10.1186/1472-6947-10-33
中图分类号
R-058 [];
学科分类号
摘要
Background: There have been no reports discussing which imaging procedures are truly necessary before treatment of endoscopically-diagnosed early gastric cancer (eEGC). The aim of this pilot study was to show which imaging examinations are essential to select indicated treatment or appropriate strategy in patients with eEGC. Methods: In 140 consecutive patients (95 men, 45 women; age, 66.4 +/- 11.3 years [mean +/- standard deviation], range, 33-90) with eEGC which were diagnosed during two years, the pre-treatment results of ultrasonography (US) and contrast-enhanced computed tomography (CT) of the abdomen, barium enema (BE) and chest radiography (CR) were retrospectively reviewed. Useful findings that might affect indication or strategy were evaluated. Results: US demonstrated useful findings in 13 of 140 patients (9.3%): biliary tract stones (n = 11) and other malignant tumors (n = 2). Only one useful finding was demonstrated on CT (pancreatic intraductal papillary mucinous tumor) but not on US (0.7%; 95% confidential interval [CI], 2.1%). BE demonstrated colorectal carcinomas in six patients and polyps in 10 patients, altering treatment strategy (11.4%; 95% CI, 6.1-16.7%). Of these, only two colorectal carcinomas were detected on CT. CR showed three relevant findings (2.1%): pulmonary carcinoma (n = 1) and cardiomegaly (n = 2). Seventy-nine patients (56%) were treated surgically and 56 patients were treated by endoscopic intervention. The remaining five patients received no treatment due to various reasons. Conclusions: US, BE and CR may be essential as pre-treatment imaging examinations because they occasionally detect findings which affect treatment indication and strategy, although abdominal contrast-enhanced CT rarely provide additional information.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] The oral health status of pre-treatment head and neck cancer patients
    S. B. Critchlow
    C. Morgan
    T. Leung
    British Dental Journal, 2014, 216 : E1 - E1
  • [32] Exploratory Evaluation of Pre-Treatment Inflammation Profiles in Patients with Colorectal Cancer
    Feier, Catalin Vladut Ionut
    Muntean, Calin
    Bolboaca, Sorana D.
    Olariu, Sorin
    DISEASES, 2024, 12 (03)
  • [33] BENEFITS OF A PRE-TREATMENT CHEMOTHERAPY EDUCATION PROGRAM FOR NEW CANCER PATIENTS
    Burgess, Debra
    Johnson, Dale
    Brennan, Laura
    ONCOLOGY NURSING FORUM, 2015, 42 (02) : E179 - E179
  • [34] Importance of Pre-treatment Screening for Substance Use and Abuse in Cancer Patients
    Rickman, K.
    PSYCHO-ONCOLOGY, 2012, 21 : 4 - 4
  • [35] Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients
    Xie Gan-Sheng
    Li Gang
    Li Yu
    Pu Jin-Xian
    Huang Yu-Hua
    Li Jin-Hu
    Yin Hu-Ming
    中华医学杂志英文版, 2019, 132 (22) : 2684 - 2689
  • [36] Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients
    Xie, Gan-Sheng
    Li, Gang
    Li, Yu
    Pu, Jin-Xian
    Huang, Yu-Hua
    Li, Jin-Hu
    Yin, Hu-Ming
    CHINESE MEDICAL JOURNAL, 2019, 132 (22) : 2684 - 2689
  • [37] Pre-treatment nutrition-related indicators and the prognosis of patients with newly diagnosed epithelial ovarian cancer: an ambispective cohort study
    Wang, Shirui
    Zhu, Jingyu
    Wu, Ningjuan
    Wang, Nannan
    Dang, Xiaohe
    Zhao, Minyi
    Zhao, Juan
    Ma, Ding
    Yang, Xiaofeng
    FRONTIERS IN NUTRITION, 2025, 12
  • [38] Pre-treatment status of inflammation-based biomarkers in the patients with advanced gastric cancer who will be treated with nivolumab.
    Kusumoto, Tetsuya
    Kudou, Kensuke
    Nanbara, Sho
    Tsuda, Yasuo
    Kusumoto, Eiji
    Hashimoto, Kenkichi
    Sakaguchi, Yoshihisa
    Ikejiri, Koji
    Oki, Eiji
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Pre-treatment levels of inflammatory markers and chemotherapy completion rates in patients with early-stage breast cancer
    Schauer, Tim
    Henriksson, Anna
    Strandberg, Emelie
    Lindman, Henrik
    Berntsen, Sveinung
    Demmelmaier, Ingrid
    Raastad, Truls
    Nordin, Karin
    Christensen, Jesper F.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (01) : 89 - 98
  • [40] Pre-treatment levels of inflammatory markers and chemotherapy completion rates in patients with early-stage breast cancer
    Tim Schauer
    Anna Henriksson
    Emelie Strandberg
    Henrik Lindman
    Sveinung Berntsen
    Ingrid Demmelmaier
    Truls Raastad
    Karin Nordin
    Jesper F. Christensen
    International Journal of Clinical Oncology, 2023, 28 : 89 - 98